Abstract
BackgroundIn 2010 two randomised trials suggested that pre-exposure prophylaxis (PrEP) products based on tenofovir, an antiretroviral drug either administered daily orally (oral PrEP) or applied topically (vaginal microbicides), significantly reduced...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have